17,261 trials
Lung Cancer
Primary: Progression-free Survival at 6 Months — 60 percentage of participants
Complicated Grief · Bereavement
Primary: Responder Status Based on Complicated Grief Clinical Global Impression-Improvement (CGI-I) Scale — 46; 38; 84; 83 percentage of responders — p=<0.05
Breast Cancer
Primary: Confirmed Response Rate — 0.67 proportion of patients
Pneumococcal Infection
Primary: Number of Participants Reporting Solicited Local and Systemic Adverse Events — 148; 153; 187; 213 participants
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Objective Tumor Response — 11.8 percentage
Juvenile Neuronal Ceroid Lipofuscinosis
Primary: Tolerability - Number of Participants Who Completed Each Arm on Assigned Study Drug Dose — 17; 19 Participants — p=0.21
Diabetes Mellitus, Type 2 · Exocrine Pancreatic Insufficiency
Primary: Part A: Serum TG Level. — 2.07; 1.68; 2.00 millimole per litre (mmol/L)
Allergic Skin Reaction
Primary: Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) — 0 participants
Lung Cancer
Primary: Overall Survival at 12 Months — 57 percentage of participants
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12) — 70.6; 100; 93.8 percentage of participants
Growth Hormone Deficiency (GHD)
Primary: Incidence of Anti-hGH Binding Antibody Formation — 1; 0; 0; 0 participants
Carney Complex · Chondrosarcoma · Gastrointestinal Stromal Tumor
Primary: Number of Participants With Complete Response or Partial Response Using Response Evaluation Criteria in Solid Tumors Guideline Version 1.1 — 0 participants
Heart Failure
Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002
Hodgkin's Disease · Lymphoma
Primary: Determine the Overall Response Rate (RR) to Bendamustine HCL in Patients With Relapsed and Primary Refractory HL. — 56 percentage of evaluable participants
Mouth Neoplasms · Head and Neck Neoplasms · Tongue Neoplasms
Primary: Percent (%) Change in Levels of pS6, pAKt473, and Ki-67 — -60.60; -67.24; -31.48; 100.00 percentage of change from baseline